MRD positive acute myeloid leukemia
Conditions
Interventions
Experimental group:Targeted activation of CIK cells
Sponsors
Beijing GoBroad Boren Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Tumor surface antigen CD33 was expressed at diagnosis in patients with acute myeloid leukemia with persistent positive gene residue or after allogeneic hematopoietic stem cell transplantation; 2. Male or female patients, aged 18-70; 3. No severe allergic constitution; 4. 0-2 points for the physical condition; 5. Estimated survival >=60 days; 6. At the initial onset, bone marrow or cerebrospinal fluid tumor cells were CD33 positive by flow cytometry or tumor tissue was CD33 positive by immunohistochemistry (CD33 positive: flow cytometry: >80% of tumor cells expressed CD33 and tumor MFI was not lower than that of the normal myeloid system; More than 80% of tumor cells expressed CD33, but MFI was lower than normal myeloid cells and CD33 expression was dim by 1log. CD33 was partially expressed in 20-80% of tumor cells. Histopathological immunohistochemistry: positive tumor cells greater than >30% were considered positive); 7. Disagree with chemotherapy and salvage bone marrow transplant patients; 8. MRD positive subjects who do not meet the conditions of allogeneic transplantation; 9. Patients with self-awareness ability need to sign the informed consent in person with a voluntary letter.
Exclusion criteria
Exclusion criteria: 1. Intracranial hypertension or brain disturbance; 2. Symptomatic heart failure or severe arrhythmia; 3. symptoms of severe respiratory failure; 4. With other types of malignant tumors; 5. Diffuse intravascular coagulation; 6. Serum creatinine and/or urea nitrogen >= 1.5 times the normal value; 7. suffering from sepsis or other uncontrollable infections; 8. Suffering from uncontrolled diabetes; 9. Severe mental disorders; 10. Brain MRI examination showed obvious intracranial lesions; 11. Have received an organ transplant (excluding bone marrow transplant); 12. Positive blood HCG test in female patients (fertile patients); 13. Screening for positive hepatitis (including hepatitis B and C), AIDS and syphilis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival time;Objective response rate;Duration of remission; | — |
Countries
China
Contacts
Public ContactDefeng Zhao
Beijing GoBroad Boren Hospital
Outcome results
None listed